Evidence map›Paper›PMID 37854474›Full record

ArticleCureus2023

Analyzing COVID-19 Vaccination Side Effects Among the Adult Population in Jeddah, Saudi Arabia.

Turki Alamri, Fahad Anwer, Nadeem S Butt, Ahmed H Alganmi, Sultan A Alotaibi, Khalid F Alzibali, Hassan A Hawsawi, Marwan Bakarman, Ahmad Azam Malik

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. The risk of DDH between breech and cephalic-delivered neonates using Graf ultrasonography.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Turki AlamriDepartment of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Fahad AnwerDepartment of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Nadeem S ButtDepartment of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Ahmed H AlganmiDepartment of Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Sultan A AlotaibiDepartment of Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Khalid F AlzibaliDepartment of Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Hassan A HawsawiDepartment of Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Marwan BakarmanDepartment of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Ahmad Azam MalikDepartment of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has brought vaccination to the forefront of global attention. The Pfizer-BioNTech vaccine, an mRNA vaccine that encodes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) glycoprotein spike, has emerged as a significant player in global vaccination efforts. It is generated from lipid nanoparticles and has been subject to various regulatory approvals and authorizations. The United Kingdom became the first country to approve the Pfizer vaccine on December 2, 2020. The World Health Organization (WHO) authorized the emergency use of the Pfizer vaccine on December 31, 2020, facilitating its production and distribution worldwide. In Saudi Arabia, as well as globally, concerns about the safety and effectiveness of vaccines have been raised. Several studies have reported side effects of the Pfizer vaccine, including rare conditions such as myocarditis. In our study, we aimed to systematically investigate the symptoms experienced after vaccination, considering the administration of three doses. We also explored the duration of these symptoms and whether they necessitated hospital visits, primary healthcare interventions, or resolved on their own. Our study employed an online cross-sectional design conducted in Jeddah, Saudi Arabia, utilizing an online self-reported survey. A total of 332 participants who met the predefined criteria were recruited for the study. The rate of COVID-19 infection after 1st and 2nd doses of Pfizer and AstraZeneca vaccines was significantly lower in middle-age subgroups (31-45 years), in comparison to young (18-30 years) and upper middle-age subgroups (46-60 years). For the AstraZeneca vaccine, the infection rate in the middle-aged group was higher after 2nd dose as compared to its 1st dose. Overall, greater infection rates were observed in upper-middle-aged subgroups with all doses of Pfizer and AstraZeneca vaccines. Fatigue and fever were the most common generalized side effects while redness/swelling/pain at the injection site, muscle pain, and joint pain were the most important local side-effects. Fatigue, fever, muscle pain, and joint pain were significantly common after 1st dose of Pfizer and fever was a significant side effect after 2nd dose of Pfizer in comparison to AstraZeneca doses. Understanding the spectrum of side effects associated with the vaccine is crucial for healthcare professionals and individuals receiving the vaccine, as it enables informed decision-making and appropriate management of potential adverse reactions.

Indexed as

covid-19fatiguepandemicside effectsvaccination

Identifiers

PMID37854474
PMCPMC10579840
OpenAlexW4387665711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.